Gilead Sciences Inc. stock outperforms competitors on strong trading day
Gilead Sciences Inc. (GILD) saw its stock advance by 5.21% to $136.36, outperforming the broader market during a grim trading session where both the S&P 500 and Dow Jones Industrial Average fell. The company's stock closed 13.31% below its 52-week high of $157.29.
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition
Novartis's recent acquisition of Myricx Bio for up to $1.5 billion highlights the robust demand for next-generation antibody-drug conjugate (ADC) technologies within the pharmaceutical sector. This transaction, part of a trend of multibillion-dollar antibody platform deals, positions VERAXA Biotech (NASDAQ: VRXA) in a lucrative market. VERAXA's proprietary BiTAC platform, which covers both ADCs and T-cell engagers, suggests potential for significant investment, strategic collaborations, and future acquisition interest as the company advances its pipeline.
Us Foods stock hits all-time high of 104.44 USD
US Foods Holding Corp. (USFD) stock has reached an all-time high of $104.44, with its current trading price at $104.63 and a market capitalization of $22.87 billion. The stock has seen significant gains over the past year and six months, reflecting strong investor confidence, though an InvestingPro analysis suggests it may be overvalued. Recent developments include major government contracts, mixed analyst ratings, and a leadership change, indicating ongoing strategic and operational shifts within the company.
Gilead Stock Rallies As Trodelvy Wins First-Line Cancer Nod
Gilead Sciences Inc. (GILD) stock rallied 3.5% after its cancer drug, Trodelvy, received FDA clearance and EU approval for first-line treatment of advanced triple-negative breast cancer, both as a monotherapy and in combination with Merck's Keytruda. HSBC upgraded GILD to Buy with a $155 target, citing underappreciated HIV therapy advancements and the new oncology catalysts. The company also reported strong financial performance with significant revenue, gross margins, and free cash flow.
RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating
RBC Capital has lowered its price target for Gilead Sciences (GILD) to $120 from $122, while keeping a "Sector Perform" rating on the stock. This adjustment reflects an updated outlook from the analyst firm. The article also notes recent analyst activities, including HSBC upgrading Gilead to Buy with a price target of $155.
Compugen (TASE:CGEN) - Stock Analysis
Compugen Ltd. (TASE:CGEN) is a clinical-stage therapeutic company focused on immuno-oncology, with a market cap of ₪645.4m. The company's stock has shown high volatility and faces forecast earnings decline, despite recent positive share price movements and progress in its clinical trials like COM701 and COM503. Compugen recently reported a move to profitability in FY 2025 but faces challenges with Q1 2026 earnings reporting a loss, with revenue expected to decline in the near future.
GILD - Gilead Sciences Inc Options
This article provides a comprehensive overview of Gilead Sciences Inc. (GILD) stock, including its latest closing price, market capitalization, financial performance metrics like income and sales, and valuation ratios. It also details dividend information, analyst recommendations, institutional and insider ownership, and various stock performance indicators.
Gilead Sciences Inc. stock outperforms competitors despite losses on the day
Gilead Sciences Inc. (GILD) shares decreased by 1.26% to $129.61 on Monday, despite an overall positive trading day for the stock market, with the S&P 500 and Dow Jones Industrial Average both seeing gains. The company's stock closed 17.60% below its 52-week high of $157.29 reached in February.
AstraZeneca PLC Stock (AZN) Moved Down by 3.79% on Jul 6: What Signal Does It Send?
AstraZeneca PLC (AZN) stock decreased by 3.79% on July 6, driven by profit-taking, revised earnings estimates, and regulatory uncertainties despite positive news like a $1.77 billion partnership with CSPC Pharmaceutical and European approval for Enhertu. Analysts have issued downward revisions for 2026 EPS, citing rising R&D costs and pipeline setbacks, including FDA delays for camizestrant and a significant clinical trial failure. The decline reflects a combination of technical overbought conditions and fundamental concerns weighing on investor sentiment.
Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More
This article details Wall Street analyst calls for Monday, July 6, 2026, highlighting upgrades for companies like T-Mobile and Gilead Sciences, and downgrades for Datadog and Pfizer. It also covers market movements following a weaker-than-expected jobs report, with gold and cryptocurrencies rising, and Treasury yields mixed. Various companies including Agnico Eagle Mines, Okta, and Glaukos received new coverage initiations.
This Gilead Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
This article details five significant analyst upgrades for Monday, July 6, 2026. Key upgrades include T-Mobile US (TMUS) by B of A Securities, U.S. Bancorp (USB) by Jefferies, Gilead Sciences (GILD) by HSBC, Tenable Holdings (TENB) by Scotiabank, and Murphy USA (MUSA) by Goldman Sachs. Each upgrade is accompanied by the analyst's new rating and price target.
Gilead Sciences stock rating upgraded to Buy by HSBC on HIV outlook
HSBC upgraded Gilead Sciences (NASDAQ:GILD) to Buy from Hold, raising its price target to $155 from $133, citing an overly pessimistic market view on HIV. The firm believes long-acting HIV therapies and pipeline assets like Yeztugo and Trodelvy will drive growth, making the stock's current valuation attractive. Additionally, significant FDA and EC approvals for Trodelvy in breast cancer treatment and Cantor Fitzgerald's reiterated 'Overweight' rating further support the positive outlook.
Zanzalintinib Trial Outcomes And Index Exit Might Change The Case For Investing In Exelixis (EXEL)
Exelixis (EXEL) recently faced removal from Russell 1000 defensive indexes and reported mixed zanzalintinib trial results, showing a statistically significant overall survival benefit in the full population but a non-significant trend in a key subgroup. These developments, coupled with an analyst downgrade due to pipeline uncertainty, intensify focus on the FDA's December 2026 decision for zanzalintinib as Exelixis seeks to diversify beyond CABOMETYX. Investors now need to critically evaluate the company's ability to build a second growth pillar and manage pipeline risks.
Amgen (AMGN) Could Be 45% Below Fair Value As Court Blocks Enbrel Price Cap
Amgen's stock is gaining momentum after a federal judge blocked Colorado's proposed 70% price cap on its key drug, Enbrel, removing a significant regulatory threat. While one fair value estimate suggests Amgen is modestly overvalued, a Discounted Cash Flow (DCF) model indicates it could be trading 45.33% below its intrinsic value. Investors are encouraged to review the valuation numbers and consider both the opportunities and risks, including potential drug pricing pressures and biosimilar competition.
Is Gilead (GILD) One of the Most Undervalued NASDAQ Stocks to Buy Right Now?
Gilead Sciences Inc. (NASDAQ: GILD) is highlighted as one of the most undervalued NASDAQ stocks after its drug Trodelvy received FDA approval as a first-line treatment for metastatic triple-negative breast cancer. This approval expands Trodelvy's utility and provides a new standard-of-care option, reinforcing Gilead's position in treating unmet medical needs. Despite the company's potential, the article suggests that some AI stocks may offer even higher returns in a shorter timeframe.
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report
Following a weak June US jobs report, healthcare stocks are gaining attention as investors rotate out of semiconductor and AI sectors. The report highlighted job growth primarily in healthcare, prompting a focus on resilient companies in this market. This article identifies three healthcare stocks—Corcept Therapeutics (CORT), Insulet (PODD), and Gilead Sciences (GILD)—that appear well-positioned for the current economic climate, offering insights into their operations, market positions, and growth prospects.
ARGX - Argen X SE ADR Options
This article provides a comprehensive overview of Argen X SE ADR (ARGX) stock, including its last closing price, financial performance metrics, and various stock indicators. It details market capitalization, income, sales, P/E ratios, EPS, insider and institutional ownership, profitability, and stock performance over different periods. The data also includes analyst recommendations and target prices.
Gilead Sciences highlights its antiviral pipeline as investors watch long-term growth potential
Gilead Sciences, a major biopharma company, is emphasizing its antiviral and growing oncology and inflammation pipelines to investors. The company, known for its HIV and hepatitis treatments, seeks to diversify its revenue streams as its established products face generic competition. Investors are keen to see how Gilead leverages cash flow to expand into new therapeutic areas and sustain long-term growth and shareholder value.
VRTX - Vertex Pharmaceuticals Inc Options
This article provides a detailed financial overview of Vertex Pharmaceuticals Inc (VRTX), including its stock performance, market capitalization, income, sales, and various financial ratios. It also highlights institutional and insider ownership, profitability margins, and analyst recommendations, offering a comprehensive snapshot of the company's financial health and market position.
Earnings call transcript: Gilead Sciences beats Q1 2026 forecasts, stock dips
Gilead Sciences reported better-than-expected Q1 2026 earnings, with non-GAAP diluted EPS of $2.03 and revenue of $7 billion, surpassing analyst forecasts. Despite the strong performance, the stock dipped 1.64% in after-hours trading. The company raised its full-year revenue guidance and provided updates on its HIV, oncology, and inflammation pipelines, including strong growth in BIKTARVY and the newly launched YES2GO.
10 Most Undervalued NASDAQ Stocks to Buy Right Now
This article identifies Diamondback Energy Inc. (NASDAQ: FANG) as one of the 10 most undervalued NASDAQ stocks to buy right now. It highlights the recent acquisition by its subsidiary, Viper Energy, of mineral and royalty interests, expanding its presence in the Permian Basin. Diamondback Energy is an independent American oil and natural gas company focused on unconventional onshore oil and gas reserves in West Texas.
10 Most Undervalued NASDAQ Stocks to Buy Right Now
This article lists the 10 most undervalued NASDAQ stocks, focusing on Diamondback Energy Inc. (NASDAQ: FANG) as an example. It highlights the recent acquisition by its subsidiary, Viper Energy, which is expanding its mineral and royalty holdings in the Permian Basin. The piece emphasizes Diamondback Energy's focus on unconventional oil and gas reserves in West Texas.
GMAB - Genmab ADR Earnings
This Finviz article provides a detailed financial overview of Genmab ADR (GMAB), including its last closing price, key financial metrics like market cap, income, sales, P/E ratio, and EPS. It also lists performance indicators, insider ownership, institutional ownership, and analyst recommendations. The data highlights recent stock performance and valuation figures for the biotechnology company.
If You Invested $1,000 in ARCELLX INC (ACLX)
If an investor put $1,000 into ARCELLX INC (ACLX) a year ago, their investment would now be worth $1,755, reflecting a 75.5% total return and a 101.2% compound annual growth rate. The article details ACLX's historical stock performance, including year-by-year returns since its trading inception in 2022. It also provides an overview of Arcellx Inc. as a clinical-stage biotechnology company focused on cell therapy and immunotherapies, particularly its lead product, anitocabtagene autoleucel (anito-cel), for multiple myeloma.
If You Invested $1,000 in Arcus Bioscience (RCUS)
This article analyzes the historical performance of investing $1,000 in Arcus Bioscience (RCUS) over various periods, showing significant returns in the last year but more modest or negative returns over longer durations. It details Arcus Bioscience's focus on developing cancer and inflammatory disease treatments, its pipeline including casdatifan, quemliclustat, domvanalimab, and zimberelimab, and its strategic collaborations with Gilead Sciences and Taiho Pharmaceutical. The company's financial approach, risk profile as a clinical-stage biopharmaceutical company, and revenue model based on collaborations rather than product sales are also discussed.
Gilead Sciences stock faces a thin data day. Business focus stays intact.
Gilead Sciences remains a key biopharmaceutical company listed on Nasdaq, with its market profile still primarily defined by its core antiviral and liver disease franchise, notably its HIV treatments like Biktarvy. In the absence of significant new data, investors will continue to focus on the company's business execution, product durability, and U.S. filing flow, as pipeline news and reimbursement trends are major catalysts for the stock. The article emphasizes that the underlying pharmaceutical model provides the most reliable framework for evaluating the stock in quiet news periods.
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
Gilead Sciences (NASDAQ: GILD) has outperformed the market over the past two decades, achieving an average annual return of 11.3%. An initial investment of $1000 in GILD twenty years ago would now be worth $8,524.03, highlighting the significant impact of compounded returns over time.
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report
Following a weak June US jobs report, investors are shifting focus to the healthcare sector for resilience as other markets become uncertain. This article highlights three healthcare stocks – Corcept Therapeutics (CORT), Insulet (PODD), and Gilead Sciences (GILD) – that offer diverse opportunities, from specialized biopharmaceuticals to medical devices and global biopharma. These companies are generating interest due to their potential for growth, strong financials, or critical market positioning amidst the changing economic landscape.
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report
Following a weak US jobs report in June, investors are shifting focus to healthcare stocks, moving away from semiconductor and AI sectors. This article highlights three healthcare companies—Corcept Therapeutics (CORT), Insulet (PODD), and Gilead Sciences (GILD)—that are well-positioned for resilience amidst economic uncertainties. Each company offers unique strengths, from pipeline advancements and recurring revenue models to strong market presence and dividends, making them attractive in the current investment climate.
AMGN - AMGEN Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for AMGEN Inc (AMGN). It covers various financial metrics, stock performance indicators, insider and institutional ownership details, as well as key valuation ratios and analyst recommendations. The information highlights AMGEN's recent financial health and market position.
REGN - Regeneron Pharmaceuticals Inc Latest SEC Filings
This article provides a detailed financial overview of Regeneron Pharmaceuticals Inc (REGN), including its latest stock performance, key financial metrics, and company statistics. It covers various aspects like market capitalization, income, sales, dividend information, analyst recommendations, and performance across different timeframes.
Insider Sell: Daniel O'Day Sells 15,000 Shares of Gilead Sciences Inc (GILD)
Daniel O'Day, Chairman & CEO of Gilead Sciences Inc (GILD), sold 15,000 shares of the company on July 1, 2026. This transaction follows a pattern of insider selling, with O'Day having sold 361,280 shares over the past year and no insider buys recorded recently. The stock is currently trading at $126.29, which is considered significantly overvalued based on its GuruFocus Value of $96.01.
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Gilead Sciences Inc. (GILD) saw its stock price rally by 4.21% to $131.27, outperforming a mixed market on Thursday. This gain occurred while the S&P 500 remained largely unchanged and the Dow Jones Industrial Average rose. Despite the strong trading day, Gilead Sciences Inc. remains 16.54% below its 52-week high.
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
Kymera Therapeutics (KYMR) stock has risen 50.9% year-to-date due to strong investor optimism surrounding its lead drug candidate, KT-621, for atopic dermatitis and asthma. The company recently completed enrollment for its phase IIb BROADEN2 study ahead of schedule, with pivotal efficacy data expected by the end of 2026. Kymera also has several other pipeline programs and collaborations, including with Sanofi and Gilead Sciences, which are contributing to its long-term value proposition and providing milestone payments.
Gilead Owed $68M In Counterfeit Case, Magistrate Judge Says
A New York federal magistrate judge has recommended that biopharmaceutical company Gilead Sciences Inc. be awarded $68 million in a case involving counterfeit HIV drugs. The recommendation stems from a lawsuit where Gilead accused several companies of producing these fake drugs, and the accused parties failed to respond to the allegations.
Gilead Owed $68M In Counterfeit Case, Magistrate Judge Says
A New York federal magistrate judge has recommended that biopharmaceutical company Gilead Sciences Inc. be awarded $68 million. This recommendation stems from a case where Gilead accused a group of companies of producing counterfeit HIV drugs, and these companies failed to respond to the allegations. The award aims to compensate Gilead for the damages incurred due to the counterfeit products.
VRTX - Vertex Pharmaceuticals Inc Dividends
This article provides a detailed financial overview of Vertex Pharmaceuticals Inc (VRTX), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It also lists key statistics such as EPS, sales growth, insider and institutional ownership, and profitability margins. The data indicates strong financial health and growth for the company, despite not paying dividends.
INSM - Insmed Inc Options
This article provides a detailed financial overview of Insmed Inc (INSM), including its stock performance, market capitalization, earnings per share, sales figures, and various financial ratios. It also lists key statistics like insider ownership, institutional ownership, and analyst recommendations. The data is presented as of June 30, with a last close price of $106.62.
BIIB - Biogen Inc Latest SEC Filings
This article provides detailed financial data and performance metrics for Biogen Inc. (BIIB), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key statistics such as EPS, sales growth, insider/institutional ownership, and price performance over different periods.
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $168
Morgan Stanley has reiterated its Buy rating on Gilead Sciences (GILD.US) and maintained its price target of $168. This indicates continued confidence in the company's stock performance according to the financial institution.
BIIB - Biogen Inc Dividends
This article provides a detailed financial overview of Biogen Inc. (BIIB), including its stock performance, key financial metrics, insider and institutional ownership, and various ratios. It highlights the company's market capitalization, income, sales, and dividend-related information, indicating current dividend estimates as null.
Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)
This article provides a Q1 earnings recap for therapeutics stocks, focusing on Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers. It highlights the strong start for Vertex, driven by its leadership in cystic fibrosis and growth in other areas, despite delivering the weakest full-year guidance update. The report also benchmarks other companies like Moderna (NASDAQ:MRNA) as the best performer and United Therapeutics (NASDAQ:UTHR) as the weakest in Q1, offering insights into their financial results and market reactions.
Gilead Sciences Inc. stock underperforms Monday when compared to competitors
Gilead Sciences Inc. (GILD) stock decreased by 1.21% on Monday, closing at $126.33, despite a strong overall market performance where the S&P 500 rose by 1.18% and the Dow Jones Industrial Average increased by 0.59%. The company's stock is currently trading 19.68% below its 52-week high of $157.29, which was reached on February 11th.
Is Zai Lab (ZLAB) A Bargain Following Its Push For More Product Launches?
Zai Lab (ZLAB) stock is currently trading around $18, significantly below its narrative fair value of $33.30, suggesting it may be undervalued. This undervaluation is attributed to expectations of increased revenue and stronger margins from multiple product launches and label expansions over the next 12-18 months. However, the company faces risks due to heavy reliance on in-licensed assets and intense oncology competition in China.
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
Merck has announced a new agreement with the ADAP Crisis Task Force (ACTF) to help state AIDS Drug Assistance Programs (ADAPs) provide access to its new once-daily HIV treatment, IDVYNSO™ (doravirine/islatravir). IDVYNSO was approved by the U.S. FDA in April 2026. This collaboration underscores Merck's commitment to expanding access to care for people living with HIV, particularly the uninsured or underserved, and addressing critical access challenges faced by state ADAP programs.
Gilead Sciences Raises Guidance After Results Top Views
Gilead Sciences (GILD) has raised its full-year guidance after exceeding second-quarter financial expectations. The biopharmaceutical company reported a revenue increase of 2% to $7.08 billion, driven by strong sales of drugs like Biktarvy, Descovy, Trodelvy, and Livdelzi. Its second-quarter profit rose to $1.96 billion, or $1.56 per share.
Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders
Fate Therapeutics Inc. (FATE) stock increased by 11.76% after releasing positive early Phase 1 data for its FT836 cancer treatment in KRAS wild-type metastatic colorectal cancer, showing meaningful tumor reductions without conditioning chemotherapy. The company's strategic profile is further strengthened by the appointment of a senior commercial leader and upcoming meetings with Piper Sandler. While FATE is a pre-revenue biotech with negative profitability, its strong balance sheet provides several years of cash runway, and the market appears to be heavily discounting pipeline risk despite positive clinical developments.
Price to sales forward of Gilead Sciences, Inc. – NASDAQ:GILD
This article focuses on the "Price to sales forward" metric for Gilead Sciences, Inc. (NASDAQ: GILD). It appears to be a stub or an auto-generated page from a financial data platform, providing minimal direct content beyond the title itself. The page structure suggests it would typically contain detailed financial information for the company.
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) received FDA approval for its drug Trodelvy for two indications in adults with triple-negative breast cancer (TNBC). The approvals cover Trodelvy as a single agent and in combination with Merck's Keytruda, for first-line treatment in specific TNBC cases. Additionally, Gilead announced European marketing authorization for Trodelvy in TNBC and FDA acceptance of a New Drug Application for Yeztugo for HIV prevention.
Healthcare markets outlook: A “dynamic” landscape ripe for M&A deals and cross-border partnerships
J.P. Morgan's mid-year outlook for the healthcare investment banking sector highlights a robust and dynamic landscape driven by M&A, cross-border partnerships, and AI adoption despite global uncertainties. Key themes include strategic urgency from patent cliffs and pipeline gaps fueling deal activity, particularly in biopharma and medtech, and an increasing role for AI in innovation, competitive positioning, and capital allocation. The report also notes companies adapting to complex regulatory environments and strengthening supply chains, all contributing to sustained M&A and capital markets momentum.
